Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Shanghai Meiyue Biotech Development Co. Ltd. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single action is assigned to 1 distinct examiner working across 1 distinct art unit. The concentration of the portfolio suggests a highly specific technical focus for the company's current intellectual property efforts, requiring a narrow but deep understanding of the relevant prior art. Practitioners should note that the limited number of active cases provides a clear and focused prosecution path without the complexity of overlapping technical arguments.
ANDERSON, REBECCA L is identified as the busiest examiner for this portfolio. This examiner is responsible for the 1 busiest examiner pending action currently on record. For practitioners, this indicates that the entirety of the company's active prosecution is consolidated under a single individual, making the examiner's specific tendencies and art unit practices the primary factor in current outcomes. Navigating this single relationship effectively is paramount, as there are no other active cases to balance the prosecution risk across the portfolio. Success in this matter will depend on addressing the specific technical requirements of the 1 distinct art unit involved.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ANDERSON, REBECCA L | 1 | 73.4% | +23.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18040966 | HETEROCYCLIC COMPOUND, PREPARATION METHOD AND USE THEREOF | ANDERSON, REBECCA L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18040966 | HETEROCYCLIC COMPOUND, PREPARATION METHOD AND USE THEREOF | ANDERSON, REBECCA L | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18040966 | HETEROCYCLIC COMPOUND, PREPARATION METHOD AND USE THEREOF | ANDERSON, REBECCA L | 1626 | §102§112 | Non-Final OA | — | Pending | Jul 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial